ASH: Pfizer, swimming in crowded waters, eyes wide impact for sickle cell, hemophilia assets

Pfizer previously reported a 92% reduction in bleeds in its phase 3 BASIS trial, with patients who received on-demand factor replacement intravenous therapy and then switched to marstacimab. The picture hasn't changed from the top-line results released in May, but the presentation at ASH provides a more in-depth illustration of the trial, including its safety data.